Listed

Acurx Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2021

Filed with the SEC on Aug 13, 2021 and accepted by EDGAR at Aug 13, 2021, 16:06 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2021-04-01 to 2021-06-30$95.1kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2021-01-01 to 2021-06-30$187.0kus-gaap:ResearchAndDevelopmentExpense
Income tax6 months2021-01-01 to 2021-06-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-04-01 to 2021-06-30−$4.0mus-gaap:NetIncomeLoss
Net income6 months2021-01-01 to 2021-06-30−$5.5mus-gaap:NetIncomeLoss
Operating cash flow6 months2021-01-01 to 2021-06-30−$876.9kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2021-06-30$17.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Total assetsAt period end2021-06-30$17.4mus-gaap:Assets
Current liabilitiesAt period end2021-06-30$1.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-06-30$1.9mus-gaap:Liabilities

Source: SEC EDGAR, the filing index for accession 0001104659-21-105074. Last ingested by Listed: Nov 14, 2026, 21:17 ET. Listed shows no prices and gives no investment advice.